hVIVO (LON:HVO) Issues Quarterly Earnings Results

hVIVO (LON:HVO) released its quarterly earnings results on Tuesday. The company reported GBX (0.82) EPS for the quarter, Digital Look Earnings reports. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%.

hVIVO Stock Performance

Shares of HVO opened at GBX 6.30 on Tuesday. The company has a market capitalization of £43.37 million, a PE ratio of -7.24 and a beta of 1.69. The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16. hVIVO has a one year low of GBX 4.30 and a one year high of GBX 11. The company’s fifty day moving average price is GBX 6.83 and its 200 day moving average price is GBX 7.42.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.